Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII. These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.[1]
Its incidence is approximately 1.5 cases/million/year.[2] The distribution is bimodal with a first period occurrence between 20 and 30 years old, which mainly corresponds to women who develop this disorder in the postpartum, and a second peak between 68 and 80 years old, corresponding to the majority of patients, with no sex difference.[3]
An underlying medical condition can be identified in up to 50% of patients, including cancer either solid or hematologic; autoimmune diseases such as rheumatoid arthritis, Sjögren syndrome, or bullous pemphigoid; administration of drugs and pregnancy. However, AHA can also emerge in elderly people without any risk factors.[4][5][6]
Overall mortality rate in AHA is varies from 20% to 70% depending on the series, attributed to the underlying disorder in about 50% of the cases, infections (5-15%) and major bleeding episodes (4%)[7][8][9]
The reason for this loss of tolerance to self-factors is still unclear. There may be different involved mechanisms, such as the presence of certain gene polymorphisms (e.g., HLA, CTLA4) and/or autoreactive CD4+ T lymphocytes.[10][11]
^Hunth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of pacients with acquired hemophilia A. Haematologica. 2009; 94: 566-75.
^Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al.Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007;109:1870-7.
^Franchini M, Vaglio S, Marano G, Mengoli C, Gentili S, Pupella S, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology. 2017; 22: 514-20.
^Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981;45:200-3.
^Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia.Blood 1993;81:1513-20.
^Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005;80:55-63.
^Knoelb P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012; 10: 622-31.
^Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2009; 20: 517-23.
^Delgado J, Jiménez-Yuste V, Hernández-Navarro F, Villar A. Acquired haemophilia: review and meta analysis focused on therapy and prognostic factors. Br J Haematol. 2003; 121: 21-35.
^Pavlova A, Zeitler H, Scharrer I, et al. HLA genotype in patients with acquired haemophilia A. Haemophilia 2010; 16:107.
^Wootla B, Desirazu N, Friboulet A, Uda T, Lacroix-Desmazes S, Kaveri S. Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies. Clinic Rev Allerg Immunol. 2009; 37: 97-104.
and 26 Related for: Acquired haemophilia information
Acquiredhaemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation...
types of haemophilia: haemophilia A, haemophilia B, haemophilia C, parahaemophilia, acquiredhaemophilia A, and acquiredhaemophilia B. Haemophilia A is a...
Haemophilia A (or hemophilia A) is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant...
a vein. It is used to treat bleeding episodes in people who have acquiredhaemophilia, among other indications. There are several disimilar forms, and...
von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization". Haemophilia. 10 (3): 199–217. doi:10.1111/j.1365-2516.2004.00894...
1980s, a large number of people in the United Kingdom – most of whom had haemophilia – were infected with hepatitis C and HIV as a result of receiving contaminated...
medication used for the treatment of bleeding episodes in adults with acquiredhaemophilia, a bleeding disorder caused by the spontaneous development of antibodies...
haemophiliacs in Japan. In 2015, Baxter split-off its haemophilia sector to create Baxalta. In 2016 Baxalta was acquired by Shire plc for $32bn. Immuno AG: Baxter...
Victoria's youngest son, Leopold, was affected by the blood-clotting disease haemophilia B and at least two of her five daughters, Alice and Beatrice, were carriers...
The HIV Haemophilia Litigation [1990] 41 BMLR 171, [1990] 140 NLJR 1349 (CA), [1989] E N. 2111, also known as AMcG002, and HHL, was a legal claim by 962...
Nicholas' and Alexandra's only son, Alexei Nikolaevich, who suffered from haemophilia. He was a divisive figure at court, seen by some Russians as a mystic...
disease: a new case of Aguadilla fibrinogen and review of the literature". Haemophilia. 21 (6): 820–827. doi:10.1111/hae.12719. PMID 25990487. S2CID 44911581...
coagulation factor concentrates for patients with bleeding disorders Haemophilia A, B and von Willebrand Disease. Immunotherapy: immunomodulation or immunoglobulin...
Willebrand EA (1926). "Hereditär pseudohemofili" [Hereditary pseudo haemophilia]. Fin Läkaresällsk Handl (in Swedish). 68: 87–112. Reproduced in Von...
aspects of Darwin's pangenesis model, which relied on acquired traits. The inheritance of acquired traits was shown to have little basis in the 1880s when...
lawsuit involving 200 Japanese haemophilia patients who had become infected with HIV as a result of using contaminated haemophilia products which were unheated...
or deficiency of which causes the abnormal bleeding associated with haemophilia type A. Kogenate is one of several commercially available Factor VIII...
company and a leading doctor in the field of haemophilia study were charged for involuntary manslaughter. Acquired immune deficiency syndrome, or AIDS, is...
Roche acquired Ventana Medical Systems for $3.4 billion. On 2 January 2009, Roche acquired Memory Pharmaceuticals Corp. On 26 March 2009, Roche acquired Genentech...
Oxford Haemophilia Centre, he was consultant physician from 1966 to 1993, and director from 1977 to 1993. Rizza was also clinical lecturer in haemophilia at...
other companies were involved in scandals related to HIV-contaminated haemophilia blood products that were sold to developing nations. In 2000, Aventis...
company's products include Elocta and Alprolix for the treatment of haemophilia; Doptelet for ITP and CLD; Kineret for several disorders; Synagis for...
Global Information